GlaxoSmithKline (GSK) is permanently discontinuing retigabine (Trobalt) from June 2017. It will no longer be available after June.
Essential Pharma has discontinued its version of ethosuximide syrup, Emeside.
If you take Emeside syrup, you will need to switch to a generic version of ethosuximide syrup. This is because the other branded version of the syrup, called Zarontin, has also been discontinued.
If you have any concerns about this, speak to your doctor, epilepsy nurse of pharmacist.
The medicine company Pfizer has stopped making its version of ethosuximide syrup, called Zarontin.
If you take Zarontin, you will need to switch to a different manufacturer’s version of ethosuximide syrup.
If you have any concerns about this, speak to your doctor, epilepsy nurse or pharmacist.
UPDATED GlaxoSmithKline (GSK) has told us it is having problems with the supply of Lamictal. This is due to manufacturing problems.
Actavis has discontinued its version of lamotrigine and there are no stocks left. This applies to both the dispersible and non-dispersible tablets.
GlaxoSmithKline (GSK), the manufacturer of retigabine (brand name Trobalt), has announced it will permanently stop making this medicine from June 2017.
Actavis have told us that they no longer have any supplies of lamotrigine.
They are unable to say if and when they may stock lamotrigine in the future.
Unlicensed Special (as Midazolam Maleate): There is a fault with around half of the bottles from batch number 73234. The neck of the adaptor, which reduces the size of the opening to accommodate the oral syringes, is the wrong size and does not fit the syringes.
We have checked stock levels with Actavis. The 5 mg tubes will be out of stock until November 2016. There are limited supplies of the 10 mg tubes in stock. Once these have run out Actavis do not know when they will be back in stock.
There is an error on the barcode of some batches of Primidone 50 mg tablets made by SERB. When the barcode is scanned, it says the tablets are 250 mg, not 50 mg tablets as it should.